<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132987">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02141178</url>
  </required_header>
  <id_info>
    <org_study_id>PRO14040418</org_study_id>
    <nct_id>NCT02141178</nct_id>
  </id_info>
  <brief_title>Comparison of Bupivacaine and Exparel for Carpal Tunnel Release</brief_title>
  <official_title>Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carpal tunnel syndrome is one of the most common surgeries performed per year in the United
      States, accounting for over 600,000 surgeries.  The procedure is commonly performed under
      light sedation and local anesthesia.  Bupivicaine, a long acting local anesthetic, has been
      used to allow extended pain relief for 8-10 hours after carpal tunnel release.  Exparel, a
      liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72
      hours post-operatively.  By decreasing post-operative pain through the use of a long-acting
      local anesthetic, the use of narcotic pain medications may be decreased and patient
      satisfaction scores may increase.

      The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine
      with respect to post-operative pain control, narcotic usage, and patient satisfaction after
      carpal tunnel release.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>Starting immediately after surgery and then every 8 hours for 10 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain will be evaluated using an 11-point ordinal scale (0-10)</description>
  </primary_outcome>
  <condition>Pain After Carpal Tunnel Release</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will received Exparel subcutaneously for local anesthesia during surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <arm_group_label>Exparel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with carpal tunnel syndrome undergoing surgery

        Exclusion Criteria:

          -  Non english speaking

          -  Allergy to bupivacaine or exparel
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Fowler, MD</last_name>
    <email>fowlerjr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Fowler, MD</last_name>
      <email>fowlerjr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>John Fowler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
